Abortion Pills, Vaccines and Food Safety: F.D.A. Nominee Heidi Overton Faces Senate Confirmation Hearing

There is a moment in every public health crisis when the difference between a regulator and an activist becomes a matter of life and death. The FDA has long been the gold standard for evidence-based decision-making, the agency that separates rigorous science from wishful thinking. A nominee who has already signaled her skepticism of two of the most studied interventions in modern medicine—childhood vaccines and reproductive health medications—raises a fundamental question: will the agency continue to follow the data, or will it follow a political agenda? Let's be precise about what is at stake. Mifepristone, when used in a medication abortion regimen, has a safety profile that rivals or exceeds that of common over-the-counter drugs like ibuprofen. It has been used by millions of women worldwide, and the FDA's own review process has repeatedly affirmed its safety. Calling it "dangerous to women" is not a scientific conclusion; it is a political framing. Similarly, the childhood vaccine schedule is not a haphazard list—it is the product of decades of epidemiological data, carefully calibrated to protect the most vulnerable among us. Reducing that schedule without evidence would be a regression with generational consequences. The broader theme here is the erosion of institutional trust. When political appointees arrive at agencies with predetermined conclusions, they don't just make bad policy—they corrode the very idea that expertise matters. The FDA's credibility is its most valuable asset. Once the public believes that decisions are made on the basis of ideology rather than evidence, the agency loses its power to protect us, and quackery fills the vacuum. We've seen this play out in the vaccine hesitancy movement, in the rise of unregulated supplements, and in the confusion around reproductive health care. None of this is to say that Dr. Overton should be presumed guilty before her hearing. She deserves a fair process, and the Senate should ask hard questions about her views on specific evidence, her commitment to following FDA science, and her plans for the agency's workforce. But the burden of proof is on the nominee. In a moment when public health is already under siege from misinformation, we cannot afford to place the FDA in the hands of someone who has already made up her mind against the science. The confirmation hearing is more than a political ritual; it is a referendum on whether we still believe in evidence. For those of us who write about health, it is a reminder that the fight for sound policy is never over. It is fought in hearing rooms, in regulatory filings, and in the quiet decisions that determine what medications are available, what vaccines are recommended, and what information reaches the public. We should be watching closely. Source: https://www.nytimes.com/2026/09/24/us/heidi-overton-fda.html